Literature DB >> 24652675

Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells.

Gabriel Brisou1, Delphine Manzoni, Stephane Dalle, Pascale Felman, Dominique Morel, Marouane Boubaya, Jean Pierre Magaud, Lucile Baseggio.   

Abstract

BACKGROUND: The rigorous cytological review by manual or automatic microscopic analysis is critical in the detection of circulating neoplastic cells, since their morphology as well as their count contributes to the diagnosis and prognosis of many diseases. However, the cytological analysis is not always obvious and requires trained and competent cytologist. In this context, the alarms and/or parameters generated by hematology analyzer could be particularly informative to alert the operators.
METHODS: Blood samples from patients with Sezary syndrome (n = 9) were studied with Sysmex XN-1000 analyzer, and compared to patients with benign or tumoral skin lesions (n = 47) and patients with chronic lymphoproliferative B-cell diseases (n = 51) used as control.
RESULTS: In present series, the value of structural lymphoid parameters (LyX and LyZ) and the alarm Blast/Abn Lympho were statistically higher in Sezary cases than in control cases. In addition, the value of LyX was associated to the count of circulating Sezary cells and value of LyZ to the presence of large Sezary cells, both parameters described as prognostic factors.
CONCLUSION: The combination of alarm Blast/Abn Lympho and structural parameters (Ly-X/Ly-Z/Ly-Y) may allow to define rule of blood slide review to screen circulating Sezary cells, and give promising results in B-cell diseases.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  diagnosis; morphology; prognosis; sezary

Mesh:

Year:  2014        PMID: 24652675      PMCID: PMC6806721          DOI: 10.1002/jcla.21744

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  16 in total

1.  T cell receptor-Vbeta analysis identifies a dominant CD60+ CD26- CD49d- T cell clone in the peripheral blood of Sézary syndrome patients.

Authors:  Enrico Scala; Maria Grazia Narducci; Paolo Amerio; Giannandrea Baliva; Romeo Simoni; Antonello Giovannetti; Lorena Silvestri; Pietro Puddu; Ornella De Pita; Giandomenico Russo
Journal:  J Invest Dermatol       Date:  2002-07       Impact factor: 8.551

2.  Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

Authors:  L Baseggio; F Berger; D Morel; M-H Delfau-Larue; G Goedert; G Salles; J-P Magaud; P Felman
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

3.  VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis.

Authors:  I Theodorou; C Bigorgne; M H Delfau; C Lahet; G Cochet; M Vidaud; M Raphael; P Gaulard; J P Farcet
Journal:  J Pathol       Date:  1996-03       Impact factor: 7.996

4.  The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.

Authors:  M G Bernengo; M Novelli; P Quaglino; F Lisa; A De Matteis; P Savoia; N Cappello; M T Fierro
Journal:  Br J Dermatol       Date:  2001-01       Impact factor: 9.302

5.  CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.

Authors:  G Rappl; J M Muche; H Abken; W Sterry; W Tilgen; S Ugurel; U Reinhold
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

6.  Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.

Authors:  P A Bunn; S I Lamberg
Journal:  Cancer Treat Rep       Date:  1979-04

7.  CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.

Authors:  Ewa Poszepczynska-Guigné; Valérie Schiavon; Michel D'Incan; Hamid Echchakir; Philippe Musette; Nicolas Ortonne; Laurence Boumsell; Alessandro Moretta; Armand Bensussan; Martine Bagot
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

8.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Authors:  Youn H Kim; Howard L Liu; Serena Mraz-Gernhard; Anna Varghese; Richard T Hoppe
Journal:  Arch Dermatol       Date:  2003-07

9.  Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.

Authors:  C B Harmon; T E Witzig; J A Katzmann; M R Pittelkow
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

Review 10.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Authors:  Elise Olsen; Eric Vonderheid; Nicola Pimpinelli; Rein Willemze; Youn Kim; Robert Knobler; Herschel Zackheim; Madeleine Duvic; Teresa Estrach; Stanford Lamberg; Gary Wood; Reinhard Dummer; Annamari Ranki; Gunter Burg; Peter Heald; Mark Pittelkow; Maria-Grazia Bernengo; Wolfram Sterry; Liliane Laroche; Franz Trautinger; Sean Whittaker
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

View more
  2 in total

1.  A Preliminary Proposal for Quality Control Assessment and Harmonization of Leukocytes Morphology-structural Parameters (cell Population Data Parameters).

Authors:  Michela Seghezzi; Sabrina Buoro; Giulia Previtali; Valentina Moioli; Barbara Manenti; Ramon Simon-Lopez; Cosimo Ottomano; Giuseppe Lippi
Journal:  J Med Biochem       Date:  2018-12-01       Impact factor: 3.402

2.  Definition of the Immune Parameters Related to COVID-19 Severity.

Authors:  Sarah Birindelli; Maciej S Tarkowski; Marcello Gallucci; Marco Schiuma; Alice Covizzi; Przemysław Lewkowicz; Elena Aloisio; Felicia Stefania Falvella; Alberto Dolci; Agostino Riva; Massimo Galli; Mauro Panteghini
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.